Drug delivery carrier and method for manufacturing the same
The microcapsule design with a hydrogel core and polymer coating addresses solubility and leakage issues, enabling effective drug delivery with sustained release properties.
Patent Information
- Application Number
- JP2025077103
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2025-05-07
- Publication Date
- 2026-11-19
AI Technical Summary
Existing drug delivery carriers face issues with low drug solubility, large pore size leading to drug leakage, and poor mechanical strength resulting in rapid dissolution and inadequate sustained release properties.
A microcapsule design comprising a hydrogel core made of a first polymer and a coating of a second polymer, formed through an ionic liquid process, allowing for a drug load of 60 to 270 mg per gram of dry weight, with the core protected by a crosslinked film.
The microcapsule design enables sufficient drug carrying capacity and excellent sustained release properties, protecting the drug from external environment and ensuring gradual release.
Smart Images

Figure 2026181648000001_ABST
Abstract
Description
[Technical Field]
[0001] The present invention relates to a drug delivery carrier and a method for producing the same. [Background technology]
[0002] Oral administration of drugs is commonly used as a treatment for diseases in the human body. Oral administration of drugs has the advantages of being less invasive, low-cost, and easy to administer, and can improve the efficacy of drugs by allowing them to act directly on specific diseases.
[0003] However, oral administration of drugs presents several challenges, including concerns about serious side effects due to absorption in undesirable parts of the body or failure of patients to adhere to prescribed dosages, as well as the need for multiple high-dose administrations due to reduced efficacy caused by physiological factors such as pH and enzymes, and the physical properties of the drug itself. Therefore, oral administration of drugs requires minimizing side effects while maintaining efficacy.
[0004] To solve the aforementioned problems, the use of drug delivery carriers has been considered (see, for example, Patent Document 1). The drug delivery carrier described in Patent Document 1 consists of an aqueous gel containing water or an aqueous solution and an alginate film covering the aqueous gel, wherein the aqueous gel contains the drug.
[0005] The drug delivery carrier described in Patent Document 1 can be manufactured by dropping an aqueous solution of alginate containing a predetermined amount of drug into an aqueous solution of a crosslinking agent that crosslinks the alginate. In this way, the alginate is crosslinked by the crosslinking agent, forming an aqueous gel containing the drug, and simultaneously forming a film that coats the aqueous gel. For example, sodium alginate can be used as the alginate, and a divalent metal salt such as calcium chloride can be used as the crosslinking agent. [Prior art documents] [Patent Documents]
[0006] [Patent Document 1] International Publication No. 2020 / 045162 [Overview of the Initiative] [Problems that the invention aims to solve]
[0007] However, the drug delivery carrier described in Patent Document 1 has the disadvantage that it cannot carry a sufficient amount of drug to obtain a sufficient therapeutic effect because the solubility of the drug in the aqueous gel is low. Furthermore, the drug delivery carrier described in Patent Document 1 has the disadvantage that the pore size of the aqueous gel is large, making it easy for the carried drug to leak out, and the mechanical strength of the alginate coating covering the aqueous gel is low, causing it to dissolve instantly in the body, making it difficult to obtain sustained release properties that allow the drug to be released gradually.
[0008] The present invention aims to eliminate such inconveniences and provide a drug delivery carrier and a method for producing the same that can carry a sufficient amount of drug to obtain therapeutic effects and has excellent sustained-release properties. [Means for solving the problem]
[0009] To achieve this objective, the drug delivery carrier of the present invention comprises a microcapsule having a core made of a hydrogel of a first polymer that carries a drug, and a coating of a second polymer that covers the core, and is characterized in that the microcapsule contains a drug in the range of 60 to 270 mg per gram of dry weight. Furthermore, the method for producing the drug delivery carrier of the present invention comprises the steps of: dissolving a drug, a crosslinking agent, and a first polymer in an ionic liquid to form an ionic liquid solution containing the drug, the crosslinking agent, and the first polymer; dropping the ionic liquid solution into an aqueous solution of a compound that is crosslinked with the crosslinking agent to form a second polymer; gelling the first polymer to form a core made of hydrogel that carries the drug, and simultaneously crosslinking the compound with the crosslinking agent to generate a second polymer and form a coating that covers the core, thereby forming a microcapsule comprising the core and the coating, and the ionic liquid solution contains a drug in the range of 60 to 270 mg per gram of dry weight of the microcapsule.
[0010] In the manufacturing method of the present invention, first, a drug, a crosslinking agent, and a first polymer are dissolved in an ionic liquid to form an ionic liquid solution containing the drug, the crosslinking agent, and the first polymer. Drugs generally have high solubility in ionic liquids, and ionic liquids can dissolve a larger amount of drug than water, but the ionic liquid solution needs to contain a drug in the range of 60 to 270 mg per gram of dry weight of the microcapsules.
[0011] In the manufacturing method of the present invention, the ionic liquid solution is then dropped dropwise into an aqueous solution of a compound that crosslinks with the crosslinking agent to form a second polymer. In this way, the ionic liquid first replaces the water contained in the aqueous solution of the compound, causing the molecules forming the first polymer to aggregate and form a structure having a three-dimensional network structure through the interaction of these molecules. The structure contains a large amount of water within the three-dimensional network structure, but is insoluble in water, and the drug is supported in the water within the three-dimensional network structure. As a result, a core is formed which is made of a hydrogel of the first polymer and supports the drug.
[0012] At the same time, the compound is crosslinked by the crosslinking agent to form a second polymer. Since the reaction that forms the second polymer occurs at the interface between the core and the aqueous solution of the compound, a film is formed on the core by the second polymer, and a microcapsule comprising the core and the film can be obtained.
[0013] The core will then carry the drug in the range that was dissolved in the ionic liquid. However, the amount of the drug is excessive relative to the water content in the core and exceeds its saturation solubility, causing the drug to precipitate within the core, and the precipitated drug particles to aggregate with each other.
[0014] The drug delivery carrier of the present invention, by including the microcapsule, can carry a sufficient amount of drug to obtain a therapeutic effect. Furthermore, according to the drug delivery carrier of the present invention, since the core of the microcapsule is covered with the coating, the drug carried on the core can be protected from the external environment. Moreover, by carrying a drug in the range of 60 to 270 mg per gram of dry matter of the microcapsule on the core, the drug precipitated in the core aggregates with each other, providing excellent sustained release properties.
[0015] If the amount of drug carried by the core is less than 60 mg per gram of dry matter of the microcapsule, excellent sustained-release properties cannot be obtained. Furthermore, it is technically difficult for the core to carry more than 270 mg of drug per gram of dry matter of the microcapsule.
[0016] In the drug delivery carrier of the present invention, the first polymer is a polymer that dissolves in an ionic liquid, and in water, the ionic liquid replaces water, causing the molecules to aggregate and form a hydrogel. For example, it is preferably cellulose.
[0017] Furthermore, in the drug delivery carrier of the present invention, the second polymer is a polymer that is crosslinked with a crosslinking agent to form a coating film that covers the core, and is preferably, for example, sodium alginate.
[0018] Further, in the drug delivery carrier of the present invention, the crosslinking agent is preferably calcium chloride. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] [Figure 1] A graph showing the drug capacity of the drug delivery carrier of the present invention. [Figure 2] A graph showing the drug release behavior of the drug delivery carrier of the present invention. DETAILED DESCRIPTION OF THE EMBODIMENTS
[0020] Next, embodiments of the present invention will be described in more detail with reference to the accompanying drawings.
[0021] The drug delivery carrier of the present embodiment includes microcapsules each having a core composed of a hydrogel of a first polymer and carrying a drug, and a second polymer film coating the core, wherein the drug is contained in a range of 60 to 270 mg per 1 g of dry matter of the microcapsules.
[0022] The drug delivery carrier of the present embodiment can be produced by a production method comprising the steps of: dissolving the drug, a crosslinking agent, and the first polymer in an ionic liquid to form an ionic liquid solution containing the drug, the crosslinking agent, and the first polymer; dropping the ionic liquid solution into an aqueous solution of a compound that is crosslinked by the crosslinking agent to form a second polymer; gelling the first polymer to form a core composed of the drug-carrying hydrogel, and at the same time, crosslinking the compound with the crosslinking agent to generate the second polymer to form a film coating the core, so as to form a microcapsule having the core and the film, wherein the ionic liquid solution contains the drug in a range of 60 to 270 mg per 1 g of dry matter of the microcapsule.
[0023] The first polymer is a polymer that dissolves in the ionic liquid, and forms a hydrogel by the ionic liquid being replaced with water in water to cause the molecules to aggregate. In the present invention, the hydrogel means a structure that is insoluble in water, while the molecules of the first polymer aggregate to form a three-dimensional network structure through interaction, and a large amount of water is contained in the three-dimensional network structure.
[0024] Examples of the first polymer include cellulose, lignin, chitin, chitosan, silk fibroin, starch, polyvinylpyrrolidone, polyvinyl alcohol, polyethylene glycol, polyethylene oxide and the like. From the viewpoint of pharmaceutical acceptability, cellulose, chitin, chitosan and the like are preferred, and cellulose is more preferred.
[0025] The second polymer is a polymer that is crosslinked by a crosslinking agent to form a film covering the core. The second polymer is not particularly limited as long as it is a polymer capable of forming a gel, and examples thereof include alginates, carrageenans, hyaluronic acid, pectin, gelatin, carboxymethyl cellulose, carboxymethyl chitosan, heparin, polyacrylic acid, polyvinyl alcohol, polyethyleneimine, polyacrylamide, polyethylene glycol, and derivatives thereof. From the viewpoint of pharmaceutical acceptability, alginates, carrageenans, carboxymethyl cellulose and the like are preferred, and sodium alginate is more preferred.
[0026] Examples of the crosslinking agent include K + , Ag + , Ca 2+ , Ba 2+ , Pb 2+ , Ni 2+ , Mn 2+ , Mg 2+ , Zn 2+ , Cu 2+ , Fe 2+ and other metal ion salts, or borates such as sodium tetraborate decahydrate (borax). From the viewpoint of low toxicity, Ca 2+Fe 2+ A salt of the Ca is preferred. 2+ Calcium chloride can be cited as an example of a salt.
[0027] The drugs applicable to the drug delivery carrier of the present invention are not particularly limited as long as they are drugs used as oral medications, and examples include antipyretics, analgesics, anticancer drugs, hormones, antibacterial agents, antiviral agents, peripheral nervous system drugs, vitamins, etc. Examples of the antipyretics and analgesics include diclofenac sodium, ibuprofen, loxoprofen sodium, acetylsalicylic acid, and acetaminophen. Examples of the anticancer drugs include doxorubicin, 5-fluorouracil, tamoxifen, docetaxel, paclitaxel, and methotrexate.
[0028] Examples of the ionic liquids include imidazolium-based ionic liquids having an acetate in an anion such as 1-ethyl-3-methylimidazolium acetate ([EMIm][OAc]) and 1-butyl-3-methylimidazolium acetate ([BMIm][OAc]), with 2 to 4 carbon atoms (general abbreviation: [CnMIm][OAc]); imidazolium-based ionic liquids having a chlorine or bromide ion in an anion such as 1-ethyl-3-methylimidazolium chloride ([EMIm]Cl) and 1-butyl-3-methylimidazolium bromide ([BMIm]Br), with 2 to 4 carbon atoms (general abbreviation: [CnMIm]X, X=Cl or Br); or 1-allyl-3-methylimidazolium chloride ([AMIm]Cl) or 1-allyl-3-methylimidazolium bromide ([AMIm]Br). The aforementioned ionic liquid may be diluted with a solvent such as dimethyl sulfoxide (DMSO) to adjust its viscosity before use.
[0029] Furthermore, unless otherwise specified, the water used in this embodiment is ultrapure water of JIS K 0557 A4 grade.
[0030] Furthermore, the drug delivery carrier of this embodiment may have a second polymer coating covering the core that contains an aminosilane such as 3-(2-aminoethylamino)propyltrimethoxysilane. The drug delivery carrier of this embodiment can have even better sustained release properties by having the second polymer coating contain the aminosilane. The drug delivery carrier of this embodiment, in which the second polymer coating contains an aminosilane, can be manufactured by stirring the drug delivery carrier obtained by the above manufacturing method in an aqueous aminosilane solution.
[0031] Next, embodiments of the present invention are shown. [Examples]
[0032] [Example 1] In this example, first, a liquid mixture of 1-butyl-3-methylimidazolium acetate ([BMIm][OAc]) (manufactured by Sigma-Aldrich, trade name: 1-butyl-3-methylimidazolium acetate) and dimethyl sulfoxide (DMSO, manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.) in a mass ratio of 60:40 is used as the solvent, and cellulose (manufactured by Sigma-Aldrich, trade name: Avicel®) is added to this solvent. PH-101 (particle size < 50 μm) was dissolved at 5% (w / v) and anhydrous calcium chloride (CaCl2, manufactured by Fujifilm Wako Pure Chemical Industries, Ltd., reagent grade (purity 97.0% or higher) was dissolved to a concentration of 0.1 mol / liter. Diclofenac sodium (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd., biochemical grade (purity 98.0% or higher)) was added to a concentration of 20 mg / ml to prepare an ionic liquid solution containing cellulose, calcium chloride, and diclofenac sodium.
[0033] Next, the ionic liquid solution was filled into a syringe fitted with a needle and added dropwise at a flow rate of 250 μL / min for 1 minute to a 1% (w / v) aqueous solution of sodium alginate (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd., Wako Grade 1, 80-120 cps (10 g / L, 20℃)) being stirred at 1000 rpm. After stirring was continued for 5 minutes, a drug delivery carrier of this embodiment was obtained, consisting of a microcapsule made of cellulose hydrogel carrying diclofenac sodium and a sodium alginate coating covering the core.
[0034] Next, the drug delivery carrier obtained in this embodiment was dried at 60°C for 12 hours or more, then placed in 42 mL of simulated intestinal fluid (SIF, pH 7.4), and shaken at 37°C and 50 rpm for 24 hours or more to release diclofenac sodium from the drug delivery carrier. The simulated intestinal fluid was an aqueous solution obtained by dissolving 8.0 g of sodium chloride (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd., reagent grade), 0.2 g of potassium chloride (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd., reagent grade), 3.6328 g of disodium hydrogen phosphate dodecahydrate (manufactured by Kanto Chemical Co., Ltd., special grade), and 0.24 g of potassium dihydrogen phosphate (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd., reagent grade) in 900 mL of ultrapure water, adjusting the pH to 7.4, and then increasing the total volume to 1 liter.
[0035] Next, the supernatant of the simulated intestinal fluid was collected, and the mass of diclofenac sodium encapsulated in the microcapsules was determined by measuring the absorbance at a wavelength of 276 nm using a UV-Vis spectrophotometer (Shimadzu Corporation, model number: UV2600i). The packing ratio of diclofenac sodium to the drug delivery carrier obtained in this example was calculated from the following equation (1).
[0036] Filling rate=W encapsulated / W dry ...(1) In formula (1), W encapsulated W is the mass of diclofenac sodium encapsulated in the microcapsule. dry This is the dry mass of the microcapsule.
[0037] The filling rate of the drug delivery carrier obtained in this embodiment was 63.8 mg per gram of dry matter of the microcapsule. The results are shown in Figure 1.
[0038] Next, the drug delivery carrier obtained in this embodiment, which had been dried as described above, was placed in 42 mL of artificial gastric juice (SGF, pH 1.2) and shaken at 37°C and 50 rpm for 2 hours. The artificial gastric juice was an aqueous solution obtained by dissolving 7 mL of concentrated hydrochloric acid (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd., reagent grade, concentration 35.0-37.0%) and 2.0 g of sodium chloride in 900 mL of ultrapure water, adjusting the pH to 1.2, and then increasing the total volume to 1 liter.
[0039] Subsequently, the drug delivery carrier was transferred to 42 mL of the simulated intestinal fluid and shaken at 37°C and 50 rpm until the entire amount of diclofenac sodium was completely released. After transferring the drug delivery carrier to the simulated intestinal fluid, 1 mL of the supernatant of the simulated intestinal fluid was periodically taken until the entire amount of diclofenac sodium was completely released, and the absorbance at a wavelength of 276 nm was measured using a UV-Vis spectrophotometer (Shimadzu Corporation, model: UV2600i) to determine the concentration C of diclofenac sodium in the simulated intestinal fluid at time t. t The following equation (2) was used to calculate the cumulative release rate of diclofenac sodium from the drug delivery carrier obtained in this embodiment.
[0040] Cumulative release rate (%)=C t / C ∞ ×100 ···(2) In formula (2), C ∞ This represents the concentration of diclofenac sodium in the simulated intestinal fluid when the entire amount of diclofenac sodium has been completely released. The results are shown in Figure 2.
[0041] [Example 2] In this example, the drug delivery carrier of this example was obtained by following the exact same procedure as in Example 1, except that diclofenac sodium as the drug was added to the exact same solvent as in Example 1 to a concentration of 50 mg / ml.
[0042] Next, the filling rate of diclofenac sodium in the drug delivery carrier obtained in this example was calculated, using the exact same procedure as in Example 1, except that the drug delivery carrier obtained in this example was used. The filling rate of the drug delivery carrier obtained in this example was 165.7 mg per gram of dry matter of the microcapsule. The results are shown in Figure 1.
[0043] Next, the cumulative release rate of diclofenac sodium from the drug delivery carrier obtained in this example was calculated, using the same procedure as in Example 1, except that the drug delivery carrier obtained in this example was used. The results are shown in Figure 2.
[0044] [Example 3] In this example, the drug delivery carrier obtained in Example 1 was placed in 10 mL of an aqueous solution of 3-(2-aminoethylamino)propyltrimethoxysilane with a pH of 7 and a concentration of 0.5 mol / liter, and stirred at 300 rpm for 5 minutes to obtain a drug delivery carrier in which the sodium alginate coating covering the core contains 3-(2-aminoethylamino)propyltrimethoxysilane (manufactured by Tokyo Chemical Industry Co., Ltd., purity of 97.0% or higher).
[0045] Next, the cumulative release rate of diclofenac sodium from the drug delivery carrier obtained in this example was calculated, using the same procedure as in Example 1, except that the drug delivery carrier obtained in this example was used. The results are shown in Figure 2.
[0046] [Example 4] In this example, the drug delivery carrier obtained in Example 2 was placed in 10 mL of an aqueous solution of 3-(2-aminoethylamino)propyltrimethoxysilane with a pH of 7 and a concentration of 0.5 mol / liter, and stirred at 300 rpm for 5 minutes to obtain a drug delivery carrier in which the sodium alginate coating covering the core contains 3-(2-aminoethylamino)propyltrimethoxysilane.
[0047] Next, the cumulative release rate of diclofenac sodium from the drug delivery carrier obtained in this example was calculated, using the same procedure as in Example 1, except that the drug delivery carrier obtained in this example was used. The results are shown in Figure 2.
[0048] [Evaluation of drug delivery carriers in Examples 1-4] Figure 1 shows that, according to the drug delivery carriers of Examples 1 and 2, the filling concentrations of diclofenac sodium as the drug were 63.8 mg and 165.7 mg, respectively, clearly demonstrating that a sufficient amount of drug can be carried to obtain therapeutic effect.
[0049] On the other hand, Figure 2 shows that it took approximately 10-11 hours for the drug delivery carriers of Examples 1 and 3, and approximately 48 hours for the drug delivery carriers of Examples 2 and 4, for the entire amount of diclofenac sodium to be released. This clearly demonstrates that the drug delivery carriers of Examples 1-4 possess excellent sustained-release properties.
[0050] Furthermore, Figure 2 clearly shows that the drug delivery carriers of Examples 3 and 4, in which the sodium alginate coating covering the core contains 3-(2-aminoethylamino)propyltrimethoxysilane, exhibit even better sustained release per unit time compared to the drug delivery carriers of Examples 1 and 2, until the entire amount of diclofenac sodium is completely released. [Explanation of symbols]
[0051] Unsigned.
Claims
1. A drug delivery carrier comprising a microcapsule having a core made of a first polymer hydrogel that carries a drug and a second polymer coating that covers the core, wherein the microcapsule contains a drug in an amount of 60 to 270 mg per gram of dry matter.
2. A drug delivery carrier according to claim 1, wherein the first polymer is a polymer that dissolves in an ionic liquid, and in water, the ionic liquid replaces water, causing molecules to aggregate and form a hydrogel.
3. A drug delivery carrier according to claim 2, characterized in that the first polymer is cellulose.
4. A drug delivery carrier according to claim 1, wherein the second polymer is a polymer that is crosslinked with a crosslinking agent to form a coating film that covers the core.
5. A drug delivery carrier according to claim 4, characterized in that the second polymer is sodium alginate.
6. A drug delivery carrier according to claim 4, characterized in that the crosslinking agent is calcium chloride.
7. A step of dissolving a drug, a crosslinking agent, and a first polymer in an ionic liquid to form an ionic liquid solution containing the drug, the crosslinking agent, and the first polymer. The process involves dropping the ionic liquid solution into an aqueous solution of a compound that is crosslinked with the crosslinking agent to form a second polymer, The process includes the steps of gelling the first polymer to form a hydrogel core that supports the drug, and simultaneously crosslinking the compound with the crosslinking agent to generate a second polymer and form a film that covers the core, thereby forming a microcapsule comprising the core and the film. A method for producing a drug delivery carrier, characterized in that the ionic liquid solution contains a drug in an amount ranging from 60 to 270 mg per gram of dry matter of the microcapsules.
Citation Information
Patent Citations
Drug delivery carrier
WO2020045162A1
